![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
University of California, Irvine |
Information provided by: | University of California, Irvine |
ClinicalTrials.gov Identifier: | NCT00257322 |
While new treatments for metastatic and recurrent colorectal cancer have become available over the past several years, this disease remains incurable with a limited life expectancy from the time of diagnosis. New strategies for treatment of disseminated colorectal cancer are needed. Under this proposal, patients with advanced colorectal cancer will receive GM-CSF to stimulate endogenous dendritic cells and enhance anti-tumor immune mechanisms. This will be combined with standard chemotherapy and patients will be followed for response and overall survival. Detailed correlative laboratory analysis will also be performed to define the extent of dendritic cell and cellular immune system stimulation.
Condition | Intervention | Phase |
Metastatic Colon Cancer Metastatic Rectal Cancer |
Drug: GM-CSF |
Phase II |
MedlinePlus related topics: | Cancer Colorectal Cancer |
ChemIDplus related topics: | Sargramostim Granulocyte-macrophage colony-stimulating factor |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | A Pilot Study of Cellular Immune Augmentation in Colon and Rectal Cancer Therapy |
Estimated Enrollment: | 40 |
Study Start Date: | April 2003 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
United States, California | |||||
Chao Family Comprehensive Cancer Center | |||||
Orange, California, United States, 92868 |
University of California, Irvine |
Principal Investigator: | Randall Holcombe, MD | Chao Family Comprehensive Cancer Center |
Responsible Party: | University of California, Irvine Medical Center ( Randall Holcombe, MD ) |
Study ID Numbers: | UCI 02-60 |
First Received: | November 18, 2005 |
Last Updated: | March 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00257322 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
![]() |